Combining immunotherapies effective against mouse model of cancer

June 19, 2017, Nationwide Children's Hospital
Credit: CC0 Public Domain

Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation and chemotherapy. However, these treatments are fraught with side effects, especially for children.

A recent study points to a new treatment strategy that takes advantage of the body's own immune response.

Over the past decade, immunotherapy has become an important part of treating some cancers effectively and with fewer side effects than traditional therapies. One immunotherapeutic approach is oncolytic virotherapy, in which a virus is used to target cancer cells specifically. Oncolytic viruses infect and kill malignant, but not normal, cells.

In the new study, researchers from Nationwide Children's Hospital used a combination of immunotherapies in a mouse model of rhabdomyosarcoma.

In addition to oncolytic virotherapy, the team also blocked the signaling of protein (PD)-1, which mediates the suppression of T-cells.

"Other researchers have recognized that if we can block the PD-1 checkpoint and unleash the T-cells a bit more, they might fight cancer better," says Timothy Cripe, MD, PhD, chief of Hematology, Oncology and Blood and Marrow Transplantation at Nationwide Children's and senior author of the study.

"We thought that if a virus infection brings in more T-cells, and the PD-1 blockade allows those cells to fight , then maybe the two therapies will work better together."

Combining the two immunotherapies delayed tumor growth and enhanced overall survival in a mouse model of rhabdomyosarcoma, says the study's first author, Chun-Yu Chen, PhD, research scientist in the Center for Childhood Cancer and Blood Diseases at The Research Institute at Nationwide Children's.

"We used a to demonstrate that when we combine oncolytic therapy with PD-1 blockade, we see a better therapeutic outcome compared to either of the therapies individually," says Dr. Chen.

The researchers say the combination is so effective because it marshals more of the T-cells that attack infections and tumors to the site of the cancer without increasing the counterbalancing, regulatory T- that suppress immune attacks.

Both oncolytic virotherapy and PD-1 blockade are FDA-approved for treating cancer; this new study provides preclinical data to support combining them in pediatric patients.

Dr. Cripe, also a principal investigator at in the Center for Childhood Cancer and Blood Diseases at The Research Institute, says his team is working with a company to determine whether they will move forward with clinical trials. They are also interested in figuring out how differences in immunogenicity might affect the success of the combination treatment.

"Our paper gives us some clues as to predictive biomarkers of who might respond best to this type of treatment," says Dr. Cripe, also a professor of Pediatrics at The Ohio State University College of Medicine. "If we can identify patients who have a tumor that is recognized by the immune system better, we can individually select patients in which this combination treatment will work best.

"It has been shown that immunotherapy works for some adult cancers; the question is, what impact will it have on childhood cancers?" says Dr. Cripe. "We are fortunate to be at an institution that has all the resources that allow us to study this in the lab and in the clinical setting and find out its full potential."

Explore further: First study of Oncolytic HSV-1 in children and young adults with cancer indicates safety, tolerability

More information: Chun-Yu Chen et al, Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models, Scientific Reports (2017). DOI: 10.1038/s41598-017-02503-8

Related Stories

First study of Oncolytic HSV-1 in children and young adults with cancer indicates safety, tolerability

May 11, 2017
HSV1716 - an oncolytic herpes simplex virus-1 - has been studied in adults via injection into the brain and superficial tumors. Now, a team of researchers at Nationwide Children's Hospital and Cincinnati Children's Hospital ...

Immune system may play key role in viral therapy's effectiveness against tumors

January 21, 2015
Viral therapy for childhood cancer could possibly improve if treatments such as chemotherapy do not first suppress patients' immune systems, according to findings published today in the journal Molecular Therapy—Oncolytics. ...

Two investigational antitumor agents work better together against MPNST and neuroblastoma

February 9, 2017
Two investigational agents, Aurora A kinase inhibitor (alisertib) and HSV1716, a virus derived from HSV-1 and attenuated by the deletion of RL1, have shown some antitumor efficacy in early clinical trials as monotherapies. ...

Immune profiling leads to implications for immunotherapy for NF1-associated tumors

June 12, 2017
Neurofibromatosis type 1 (NF1)—an autosomal dominant disorder affecting approximately one in every 3,500 people—results in dysfunctional neurofibromin, a protein expressed throughout the body and involved in the RAS signaling ...

Doctors look at treating specific types of pediatric cancer with viral therapy

September 10, 2013
(Medical Xpress)—Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children's ...

Adenoviruses and the immune system join forces against cancer

February 16, 2017
Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute (IDIBELL), led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.